Biotech takeover merry-go-round picks up speed! BioNTech, Evotec, Merck, and BioNxt Solutions!

BioNxt Solutions: Takeover after the big announcement?

Is BioNxt Solutions sprucing itself up for a takeover? The Company specializes in the development of advanced drug delivery technologies. The day before yesterday, it announced that, in parallel with product candidates such as BNT23001, it is working on a potentially groundbreaking platform for the targeted delivery of chemotherapeutic agents. By localising toxic chemotherapeutic agents in tumors, the Company aims to address an important unmet need in precision oncology.

The goal is smarter chemotherapy. To achieve this, the Company's proprietary Targeted Drug Delivery System (TDDS) uses a novel, dual-action mechanism: Highly effective chemotherapeutic agents are first concentrated in the immediate vicinity of tumors, and free drug molecules outside the tumor are then quickly neutralized to protect healthy tissue.

In vitro studies have demonstrated that therapeutic efficacy can be increased tenfold and the safety of healthy cells can be protected. The BioNxt platform is designed to be compatible with more than 100 established chemotherapeutic agents and oncological therapies. This also applies to generic molecules and preparations that have been considered too toxic for systemic use. BioNxt is now seeking collaborations with pharmaceutical companies in the form of joint development, out-licensing, or license supply agreements. Some may want to secure the platform in its entirety right away. After all, it addresses a billion-dollar market, and with a market capitalization of less than EUR 50 million, BioNxt Solutions is certainly not overvalued.

Merck swallows Verona

Merck has recently demonstrated how quickly acquisitions can sometimes happen. With the acquisition of Verona Pharma, the US pharmaceutical company has taken another step toward expanding its portfolio in the field of respiratory diseases. According to the Company, the purchase price is around USD 10 billion. The focus is particularly on ensifentrin, an innovative inhaled drug for the treatment of chronic obstructive pulmonary disease (COPD), which is currently in the approval phase with the US Food and Drug Administration (FDA). The acquisition provides Merck with early access to a potentially high-revenue drug in a therapeutic area with significant medical need and a growing market volume.

With this deal, Merck is following the industry trend of acquiring promising biotech pipelines through acquisitions. In times of increasing competition and expiring patents, many large pharmaceutical companies are investing in innovative active ingredients from young companies. The acquisition not only provides Merck with a drug of blockbuster potential but also an experienced team specializing in inhalation therapies – a field in which Merck has had a relatively limited presence to date.

BioNTech and Evotec: Where is the journey headed?

And where is the journey headed for BioNTech and Evotec? When it comes to development cooperation, BioNxt Solutions can look to BioNTech as a model. The billion-dollar deal between the German biotech company and Bristol-Myers Squibb (BMS) was a real bombshell. BMS will support the development of BioNTech's bispecific antibody candidate BNT327 in a range of solid tumor types, and if successful, the partners will share revenue and profits. In return, BioNTech will receive a total of USD 3.5 billion by 2028. Milestone payments could add up to USD 7.6 billion.

Following the announcement, the share price experienced a jump, but calm has since returned to the stock. Following profit-taking, the security is now approaching resistance at EUR 100 again. Analysts currently see BioNTech as a buying opportunity with moderate to high upside potential. According to Aktien Guide, 20 out of 27 analysts recommend buying the stock. There are currently no Sell recommendations. The average price target is around USD 140.

When it comes to acquisitions in the biotech sector, the name Evotec always comes up. Shareholders are hoping that takeover speculation will resurface. However, there are currently no signs of this. The share price has been hovering around EUR 7 for months. Deutsche Bank considers it to be fairly valued. Analysts do not expect the second-quarter report to provide any positive impetus. Their target price is EUR 7, and their rating is consequently "Hold."

BioNxt Solutions is increasingly becoming a takeover candidate. But even without a takeover, there are many reasons to believe that the share price will rise. The Company is working on exciting products and has another ace up its sleeve with its new platform. In contrast, Evotec appears to have lost momentum at the moment. BioNTech, on the other hand, with its full pipeline, is a core investment in the biotech sector.